Isofol publishes 2025 reports as arfolitixorin program shows progress

Isofol Medical AB ( (SE:ISOFOL) ) has shared an announcement.

Isofol Medical AB has published its annual report and corporate governance report for the 2025 financial year, making both the Swedish original and an English translation available on its website for investors and other stakeholders. The disclosure underscores the company’s transparency as it navigates a pivotal period in its clinical and regulatory strategy.

Chief executive Petter Segelman Lindqvist said Isofol made clear progress in 2025 by refocusing on the clinical development of its cancer drug candidate arfolitixorin and later reporting positive preliminary interim results from an ongoing study. The company also advanced regulatory discussions, deepened its collaboration with partner Solasia Pharma K.K., and strengthened its financial position, developments that could bolster its prospects in the oncology biotech space and support future funding and partnership opportunities.

The most recent analyst rating on (SE:ISOFOL) stock is a Hold with a SEK0.62 price target. To see the full list of analyst forecasts on Isofol Medical AB stock, see the SE:ISOFOL Stock Forecast page.

More about Isofol Medical AB

Isofol Medical AB is a clinical-stage biotechnology company listed on Nasdaq Stockholm and focused on improving outcomes for patients with severe forms of cancer. Its lead drug candidate, arfolitixorin, is a next-generation folate-based treatment intended to enhance the efficacy of standard therapies for several solid tumors and is currently being evaluated in a phase Ib/II study in colorectal cancer, one of the world’s most common and hard-to-treat malignancies.

Average Trading Volume: 1,482,548

Technical Sentiment Signal: Strong Sell

Current Market Cap: SEK196.8M

Learn more about ISOFOL stock on TipRanks’ Stock Analysis page.